Real-world experience on off-label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna.

Like Comment
Because of the tendency of lentigo maligna (LM) for subclinical extension, staged excisions with margin control achieve lower recurrence rates than conventional wide local excision (0-9.5% vs 8-20%). However, these surgical techniques are limited by their requirement in time, costs and training.

View the full article @ The British journal of dermatology

Get PDF with LibKey
Authors: A Lallas, E Moscarella, H Kittler, C Longo, L Thomas, I Zalaudek, A Kyrgidis, S M Manoli, N di Meo, C Papageorgiou, Z Apalla, G Argenziano


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
6577 Contributions
0 Following